Grey Healthcare Hong Kong wins Roche Avastin, Xeloda PR accounts

Xeloda launched in Hong Kong over a decade ago while Avastin is a new entrant to the market.

"We are very pleased to gain these two leading brands from Roche," Dorothy Yung, director of client service of Grey Healthcare Hong Kong said. "With the aging population in Hong Kong, cancer cases are getting more prevalent, cancer treatment development has become a key focus for many of the leading pharmacutical companies, and they are launching more and more new oncology products, and allocating more marketing resources in this market segment."

The agency has formed an oral chemotheraphy advocacy group consisting of oncology specialists, nurses, patient groups, pharmacists and pharmaco-economists. The results of their meetings will be sent to the Hospital Authority.